CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth

CDT Equity (Nasdaq: CDT) announced stockholders approved all proposals at the Special Meeting held March 17, 2026.

Rhea-AI Summary

CDT Equity (Nasdaq: CDT) announced stockholders approved all proposals at the Special Meeting held March 17, 2026. Key highlights include a $123M investment in Sarborg, expansion of the company IP portfolio, potential access to new capital, and a targeted annual overhead of less than $8 million.

The company says its AI-driven platform can analyze more than 3,000 diseases in hours versus conventional timelines, and CDT is shifting toward out-license deals with disease-specific partners and funds.

Positive

• $123M investment in Sarborg completed
• Annual overhead targeted under $8 million
• AI analysis capability over 3,000 diseases in hours

Negative

• None.

Argus Mar 18 session

+3.78% close to close Open Argus

Details

News Market Reaction – CDT

On Mar 18, the day this news came out, CDT closed 3.78% above the previous close.

Data tracked by StockTitan Argus for the Mar 18 session.

Market Context

This announcement confirms stockholder approval of all special meeting proposals, supporting CDT’s A...

Analysis

This announcement confirms stockholder approval of all special meeting proposals, supporting CDT’s AI-led drug repurposing strategy and its $123M Sarborg investment. Management highlights a tightly managed annual overhead of less than $8 million and the ability to analyze over 3,000 diseases rapidly. In parallel, recent filings describe sizable pre-funded warrant issuances, reverse split authority, and a $25 million equity line, so investors may watch how capital-structure changes interact with execution on out-licensing and partnership plans.

Key Figures

Investment in Sarborg: $123M Annual overhead: < $8 million Disease analyses: > 3,000 diseases +5 more

Investment in Sarborg

$123M

Described as transforming CDT through this investment

Annual overhead

< $8 million

CEO cites carefully controlled annual overhead

Disease analyses

> 3,000 diseases

AI platform analysis capacity in hours vs conventional timelines

Equity line capacity

$25 million

Equity line permitting up to this amount or 19.99% share issuance

December pre-funded warrants

3,685,815 shares

Shares issuable upon exercise, subject to approval

February pre-funded warrants

109,978,918 shares

Shares issuable upon exercise, subject to stockholder approval

Reverse split range

1-for-2 to 1-for-100 (up to 1-for-250)

Board authority requested for potential reverse stock splits

Shares outstanding

4,420,963

Common shares outstanding as of the record date in PRE 14A

Historical Context

5 past events · Latest: Mar 12

5 events

1. Mar 12

   Sarborg rare disease deal

   24h Move

   +2.6%

   Update on Sarborg collaboration using ~1,700 rare disease signatures to map assets.

2. Mar 05

   AI patent filing

   24h Move

   -5.8%

   Sarborg U.S. provisional patent for AI Signature Agent; CDT holds 20% stake.

3. Mar 04

   Growth positioning

   24h Move

   +14.2%

   Strategic update on pharma portfolio and $115M 20% Sarborg equity acquisition.

4. Feb 24

   Platform expansion

   24h Move

   -4.3%

   Sarborg AI platform expansion into bacteria and agrochemicals; CDT retains 20% stake.

5. Feb 20

   Sarborg acquisition

   24h Move

   -19.3%

   Agreement to acquire 20% of Sarborg for $115M in shares and pre-funded warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-funded warrants, equity line, reverse stock splits, at-the-market, +3 more

7 terms

pre-funded warrants financial

"approval to issue 3,685,815 shares upon exercise of December pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

equity line financial

"approval of an equity line permitting up to $25 million or 19.99%"

An equity line is a financing arrangement that lets a company raise cash over time by issuing new shares up to an agreed limit to an investor or through a placement program. It acts like a tapable credit line paid with stock rather than cash, giving the company flexible funding for operations or growth while reducing each existing share's ownership proportion; investors watch these deals because they affect share supply and shareholder value.

reverse stock splits financial

"authority to effect one or more reverse stock splits at ratios between 1-for-2 and 1-for-100"

A reverse stock split is when a company combines multiple existing shares into fewer higher-priced shares—like trading four small slices of a pie for one larger slice. It doesn’t change the overall value of an investor’s holdings immediately, but it raises the per-share price and can matter to investors because it can affect market perception, stock exchange listing eligibility, and trading liquidity, and it changes share counts used in investor metrics.

at-the-market financial

"its remaining at‑the‑market capacity of approximately $1.8 million was utilized"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

shelf registration statement regulatory

"[S-3] CDT Equity Inc. Shelf Registration Statement"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus regulatory

"Prospectus Filed Pursuant to Rule 424(b)(3)"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

schedule 13g regulatory

"an amendment to Schedule 13G, states Sarborg beneficially owns 123,595 shares"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that all proposals put forth at the Special Meeting of Stockholders of CDT, held on Tuesday, March 17, 2026, were duly passed by the stockholders.

“Following the successful passing of all the proposals at yesterday’s Special Meeting, CDT Equity continues to transform through its $123M investment in Sarborg, the continued expansion of its IP portfolio, potential access to significant new capital and a carefully controlled annual overhead of less than $8 million,” said Dr. Andrew Regan, Chief Executive Officer. “Utilizing cutting edge AI and an algorithmic approach, CDT can complete analysis on more than 3,000 diseases in a matter of hours, that might conventionally have taken pharma companies up to 5 years. It’s a breakthrough in drug re-purposing that uniquely positions the Company through a novel approach, which combined with CDT’s focus on developing IP is expected to revolutionize the approach of pharmaceutical companies. CDT Equity is now moving to a phase of out-license deals with disease specific partners and funds.”

For further information or to discuss potential partnership opportunities, please contact the Company at info@cdtequity.com.

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to, the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors
CDT Equity Inc.
Info@cdtequity.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CDT (CDT) stockholders approve at the March 17, 2026 special meeting?

Stockholders approved all proposals at the March 17, 2026 special meeting, enabling strategic actions. According to the company, approvals support its $123M investment in Sarborg, IP expansion, and steps toward out-license deals and potential capital access.

How large is CDT's investment in Sarborg and why does it matter for CDT (CDT)?

CDT made a $123M investment in Sarborg, a material strategic transaction. According to the company, the investment positions CDT to expand its IP portfolio and pursue disease-specific out-license partnerships.

What is CDT's stated annual overhead after the March 2026 decisions?

CDT cites a carefully controlled annual overhead of less than $8 million following recent actions. According to the company, this cost discipline is intended to preserve capital while pursuing partnerships and IP development.

What capability does CDT claim for its AI platform and how might that affect drug repurposing?

CDT claims its AI can analyze more than 3,000 diseases in hours, accelerating research timelines dramatically. According to the company, this algorithmic approach aims to shorten analyses that could otherwise take years for pharma companies.

Is CDT moving to licensing deals after the March 2026 approvals and what does that mean for investors?

CDT said it is moving to out-license deals with disease-specific partners and funds as its next phase. According to the company, this shift focuses on monetizing IP via partnerships rather than sole internal commercialization.

Will the March 17, 2026 approvals give CDT (CDT) access to new capital?

The company indicated potential access to significant new capital as part of its post-meeting plans. According to the company, approvals and the Sarborg investment are intended to enhance financing options for growth and partnerships.